The earnings call highlighted several positive developments, including successful trial results, regulatory progress, and commercial readiness for ziftomenib. However, these positive aspects are counterbalanced by increased expenses and a significant net loss in the quarter.

Company Guidance -

Q3 2025

During Kura Oncology's Second Quarter 2025 conference call, the company provided extensive updates on its lead program, ziftomenib, particularly in addressing acute myeloid leukemia (AML). Ziftomenib showed promising results in the KOMET-001 trial, with a 23% CR/CRh rate in relapsed/refractory NPM1-mutated AML patients and a 63% MRD-negative rate among responders. The FDA has accepted the new drug application for ziftomenib, granting priority review with a PDUFA target action date of November 30, 2025. Kura is preparing for commercialization in collaboration with Kyowa Kirin, aiming to impact up to 50% of AML patients through two Phase III trials under the KOMET-017 protocol. Financially, Kura reported $630.7 million in cash and equivalents as of June 30, 2025, with the potential to receive up to $375 million in additional milestones from its Kyowa Kirin partnership. The company also highlighted ongoing progress in its farnesyl transferase inhibitor program, with three clinical abstracts accepted for the 2025 ESMO Congress.

Positive Trial Results for Ziftomenib

The KOMET-001 trial showed promising results for ziftomenib monotherapy in relapsed/refractory NPM1-mutated AML patients, with a CR/CRh rate of 23% and 63% of responders being MRD negative.

Regulatory Progress for Ziftomenib NDA

The FDA accepted the NDA for ziftomenib in relapsed/refractory NPM1-mutant AML, granting priority review with a PDUFA target action date of November 30, 2025.

Commercial Readiness for Ziftomenib Launch

Pre-commercial activities are underway to prepare for potential approval, including building commercial supply, advancing inspection readiness, and recruiting and training a sales force.

Financial Position and Collaboration Revenue

Kura reported $15.3 million in collaboration revenue from Kyowa Kirin and has $630.7 million in cash, cash equivalents, and short-term investments, which should fund operations into 2027.

Kura Oncology (KURA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

KURA Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 30, 2025	2025 (Q3)	-0.73 / -	-0.63	―	―	―
Aug 07, 2025	2025 (Q2)	-0.37 / -0.75	-0.59	-27.12% (-0.16)	―
May 01, 2025	2025 (Q1)	-0.60 / -0.66	-0.59	-11.86% (-0.07)	―
Feb 26, 2025	2024 (Q4)	-0.64 / -0.22	-0.55	60.00% (+0.33)
Nov 07, 2024	2024 (Q3)	-0.63 / -0.63	-0.5	-26.00% (-0.13)
Aug 08, 2024	2024 (Q2)	-0.63 / -0.59	-0.53	-11.32% (-0.06)
May 02, 2024	2024 (Q1)	-0.55 / -0.59	-0.5	-18.00% (-0.09)
Feb 27, 2024	2023 (Q4)	-0.55 / -0.55	-0.49	-12.24% (-0.06)
Nov 02, 2023	2023 (Q3)	-0.54 / -0.50	-0.53	5.66% (+0.03)
Aug 03, 2023	2023 (Q2)	-0.54 / -0.53	-0.52	-1.92% (-0.01)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

KURA Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$5.96	$5.54	-7.05%
May 01, 2025	$6.49	$6.47	-0.31%
Feb 26, 2025	$7.77	$7.65	-1.54%
Nov 07, 2024	$17.77	$17.68	-0.51%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Kura Oncology (KURA) report earnings?

Kura Oncology (KURA) is schdueled to report earning on Oct 30, 2025, After Close (Confirmed).

What is Kura Oncology (KURA) earnings time?

Kura Oncology (KURA) earnings time is at Oct 30, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is KURA EPS forecast?

KURA EPS forecast for the fiscal quarter 2025 (Q3) is -0.73.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing